Personalized Medicine – Products

PlaqueTec announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

Glox Therapeutics, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

Oligonucleotide therapeutics (OTs) show great promise in the field of personalized medicine as a method of targeting undruggable proteins.

Microarray-based solution enables deeper investigations of the humoral immune response in disease biology.

ScreenIn3D reports on how their proprietary lab-on-a-chip technology is enabling cancer researchers to miniaturize their testing of biopsy tissue samples across a wide range of modalities and to test both single and combination drug therapies.

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms.

A team of scientists led by the University of Oxford have achieved a significant breakthrough in detecting modifications on protein structures.

A landmark study demonstrates that precision oncology medicines could deliver a superior return on Investment for Pharma R&D vs their one size fits all counterparts.

Eremid® Genomic Services, LLC (“Eremid”) announces a significant expansion of its in-house sequencing capabilities with the installation of PacBio’s latest HiFi sequencing platform, the Revio.